Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 108 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $115,676 | -67.9% | 23,704 | -5.1% | 0.00% | – |
| Q3 2022 | $360,000 | +13.6% | 24,977 | +19.4% | 0.00% | – |
| Q2 2022 | $317,000 | +39.0% | 20,924 | +8.6% | 0.00% | – |
| Q1 2022 | $228,000 | -22.4% | 19,265 | +6.6% | 0.00% | – |
| Q4 2021 | $294,000 | -39.1% | 18,066 | +6.6% | 0.00% | – |
| Q3 2021 | $483,000 | -8.3% | 16,942 | +8.8% | 0.00% | – |
| Q2 2021 | $527,000 | +18.4% | 15,567 | +5.8% | 0.00% | – |
| Q1 2021 | $445,000 | -67.8% | 14,716 | -47.3% | 0.00% | -100.0% |
| Q4 2020 | $1,383,000 | +22.2% | 27,939 | -5.2% | 0.00% | 0.0% |
| Q3 2020 | $1,132,000 | -29.5% | 29,476 | -20.7% | 0.00% | 0.0% |
| Q2 2020 | $1,605,000 | +190.2% | 37,156 | +75.5% | 0.00% | – |
| Q1 2020 | $553,000 | -43.3% | 21,174 | -32.2% | 0.00% | -100.0% |
| Q4 2019 | $976,000 | +296.7% | 31,245 | +231.9% | 0.00% | – |
| Q3 2019 | $246,000 | – | 9,415 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |